Altus Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Altus Pharmaceuticals
Starting stock price: $19.19
Ending stock price: $5.18
Percent Change: -73.01%

Details: In July Altus lost orphan drug status for its experimental pancreatic insufficiency therapy; the FDA said the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. But the real blow came in December when Genentech return the North American rights to ALTU-238, a growth hormone. Altus is looking for another partner for the drug.

More News:
Altus shares dive as Genentech hands back drug rights. Report
Altus loses orphan drug status. Report
Altus inks $140M pact for human growth hormone. Report
Altus stock plunges on clinical trial delay. Report

Altus Pharmaceuticals - Worst Pharma Stocks of 2007

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.